Evidence map›Paper›PMID 41090788›Full record

ArticleCells2025

The Protein Tyrosine Phosphatase 1B Modulates the Activation of Yes-Associated Protein and Sensitizes to Cytotoxic Chemotherapy in Preclinical Models of Cholangiocarcinoma.

Ryan D Watkins, Jennifer L Tomlinson, EeeLN H Buckarma, Hendrien Kuipers, Danielle M Carlson, Nathan W Werneburg, Daniel R O'Brien, Chen Wang, Rory L Smoot

Abstract read
In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ryan D WatkinsDepartment of Surgery, Mayo Clinic, Rochester, MN 55905, USA.
Jennifer L TomlinsonDepartment of Surgery, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0002-0909-3165
EeeLN H BuckarmaDepartment of Surgery, Mayo Clinic, Rochester, MN 55905, USA.
Hendrien KuipersDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA.
Danielle M CarlsonDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA.
Nathan W WerneburgDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA.
Daniel R O'BrienDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA.
Chen WangDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA.
Rory L SmootDepartment of Surgery, Mayo Clinic, Rochester, MN 55905, USA.

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
PILOT AND FEASIBILTY PROGRAMP30DK084567 · NIDDK · MAYO CLINIC ROCHESTER · PI GREGORY J. GORES · 2009 to 2026
$22.2M
Project 4: ImmunovirotherapyP50CA210964 · NCI · MAYO CLINIC ROCHESTER · PI Rory Smoot · 2018 to 2026
$20.5M
Mayo Clinic Center for Cell Signaling in Gastroenterology P30DK084567Mayo Clinic Medical Genome Facility - Proteomics Core NCI Cancer Center Support Grant 5P30 CA15083-43C1NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA210964NIDDK NIH HHS P30 DK084567
6 · The paper itself

Abstract

Lacking effective therapeutics, cholangiocarcinoma (CCA) remains a deadly malignancy of the biliary tract. The Hippo pathway effector protein Yes-associated protein (YAP) is implicated in CCA pathogenesis and chemotherapeutic resistance; however, the oncogenic mechanisms underlying YAP regulation remain incompletely understood. An enhanced understanding of YAP and its role in CCA may uncover novel therapeutic targets and better define resistance pathways. Human CCA cells and murine syngeneic CCA models were utilized to explore the molecular relationship of YAP and protein tyrosine phosphatase 1B (PTP1B). Previous work in CCA has demonstrated that YAP interacts with multiple protein tyrosine phosphatases, including SHP2 and PTP1B. We observed that PTP1B pharmacologic inhibition was associated with increased cell proliferation and YAP target gene expression, while genetically enforced overexpression of PTP1B was associated with a decrease in YAP activation. Treatment of CCA cells

Indexed as

Adaptor Proteins, Signal TransducingAntineoplastic AgentsBile Duct NeoplasmsCholangiocarcinomaProtein Tyrosine Phosphatase, Non-Receptor Type 1AnimalsCell Line, TumorCell ProliferationCisplatinDeoxycytidineDisease Models, AnimalGemcitabineHumansMiceYAP-Signaling ProteinsAdaptor Proteins, Signal TransducingAntineoplastic AgentsCisplatinDeoxycytidineGemcitabineProtein Tyrosine Phosphatase, Non-Receptor Type 1PTPN1 protein, humanYAP1 protein, humanYAP-Signaling Proteinscisplatingemcitabinehippo pathwaytyrosine phosphatase

Identifiers

PMID41090788
PMCPMC12523963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.